Macrophage hypoxia signaling regulates cardiac fibrosis via Oncostatin M.
Hajime AbeNorihiko TakedaTakayuki IsagawaHiroaki SembaSatoshi NishimuraMasaki Suimye MoriokaYu NakagamaTatsuyuki SatoKatsura SomaKatsuhiro KoyamaMasaki WakeManami KatohMasataka AsagiriMichael L NeugentJung-Whan KimChristian StockmannTomo YonezawaRyo InuzukaYasushi HirotaKoji MaemuraTakeshi YamashitaKinya OtsuIchiro ManabeRyozo NagaiIssei KomuroPublished in: Nature communications (2019)
The fibrogenic response in tissue-resident fibroblasts is determined by the balance between activation and repression signals from the tissue microenvironment. While the molecular pathways by which transforming growth factor-1 (TGF-β1) activates pro-fibrogenic mechanisms have been extensively studied and are recognized critical during fibrosis development, the factors regulating TGF-β1 signaling are poorly understood. Here we show that macrophage hypoxia signaling suppresses excessive fibrosis in a heart via oncostatin-m (OSM) secretion. During cardiac remodeling, Ly6Chi monocytes/macrophages accumulate in hypoxic areas through a hypoxia-inducible factor (HIF)-1α dependent manner and suppresses cardiac fibroblast activation. As an underlying molecular mechanism, we identify OSM, part of the interleukin 6 cytokine family, as a HIF-1α target gene, which directly inhibits the TGF-β1 mediated activation of cardiac fibroblasts through extracellular signal-regulated kinase 1/2-dependent phosphorylation of the SMAD linker region. These results demonstrate that macrophage hypoxia signaling regulates fibroblast activation through OSM secretion in vivo.
Keyphrases
- transforming growth factor
- epithelial mesenchymal transition
- left ventricular
- endothelial cells
- adipose tissue
- signaling pathway
- stem cells
- heart failure
- transcription factor
- multidrug resistant
- gene expression
- protein kinase
- genome wide
- physical activity
- dna methylation
- weight gain
- anti inflammatory
- body mass index
- liver fibrosis